Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Clinical utility of labeled cells for detection of allograft rejection and myocardial infarction

Journal Article · · Semin. Nucl. Med.; (United States)
The choice of a specific radiolabeled blood component for use in detection of allograft rejection depends on several factors including the immunosuppressive agents used, the type of organ allografted, and particularly the length of time the allograft resides in the host and the duration of rejection. To date, only the use of 111In-labeled platelets in renal allograft recipients immunosuppressed with azathioprine and corticosteroids has shown clinical promise in the detection of early allograft rejection. Radiolabeled blood components are unlikely to play a significant role in detection of myocardial infarction. The use of these agents for monitoring therapeutic interventions or as indicators of prognosis in patients with myocardial infarction continues to be investigated.
Research Organization:
Columbia Univ., New York, NY
OSTI ID:
6053550
Journal Information:
Semin. Nucl. Med.; (United States), Journal Name: Semin. Nucl. Med.; (United States) Vol. 14:3; ISSN SMNMA
Country of Publication:
United States
Language:
English